Consultation on Acnecide face gel and face wash
Read the full outcome
Detail of outcome
The Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Acnecide Face Gel and Acnecide Face Wash from pharmacy (P) to general sale list (GSL) medicines for the treatment of mild acne affecting the face in adults and adolescents aged 12 years and over. See the public assessment report above for more information.
Feedback received
Detail of feedback received
Consultation ARM 98 which summarises the proposal for pharmacy (P) to general sale list (P to GSL) reclassification of Acnecide Face Gel and Acnecide Face Wash was posted on the GOV.UK website on 9 May 2019. The deadline for comments was given as 30 May 2019.
Eight responses were received. Four responses (from patients/members of the public) were in favour of the reclassification. Four responses (two from professional bodies/associations representing pharmacists, one from a pharmacy trade body and one from a pharmaceutical company regulatory affairs consultant) were not in favour.
Original consultation
Consultation description
We are proposing to make Acnecide ‘Face’ products available from general sales outlets with more limited conditions of use than the current pharmacy products.
The products are Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel. They are preparations (face gel and face wash) containing benzoyl peroxide intended for use on the face.
They are for the treatment of mild acne affecting the face in adults and adolescents aged 12 years and over.
The Commission on Human Medicines (CHM) has advised that Acnecide `Face’ products can be available as General Sale List (GSL) medicines.
This deadline for comments was 5:00pm on 30 May 2019.
Documents
Updates to this page
Published 9 May 2019Last updated 23 September 2019 + show all updates
-
Uploaded public assessment report (PAR) and updated final outsome/summary text of consultation.
-
First published.